NEW: No-Cost Streetwise Reports Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
GW is the global leader in developing cannabinoid-based medicines. Its lead product candidate, Epidiolex® (cannabidiol), is in development to treat rare and catastrophic forms of childhood-onset epilepsy, potentially offering relief to patients for conditions that previously had few treatment options.
© 2020 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
